Donepezil

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Cognitively Normal Elderly Individuals

Conditions

Cognitively Normal Elderly Individuals

Trial Timeline

Jan 1, 2006 → Mar 1, 2009

NCT ID

NCT00220896

About Donepezil

Donepezil is a approved stage product being developed by Eisai for Cognitively Normal Elderly Individuals. The current trial status is completed. This product is registered under clinical trial identifier NCT00220896. Target conditions include Cognitively Normal Elderly Individuals.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02787746	Approved	Completed	Apr 1, 2016	Mar 1, 2019	Alzheimer's Disease
NCT02550665	Phase 3	Completed	Dec 1, 2014	Oct 1, 2016	Alzheimer's Disease
NCT01023425	Pre-clinical	Completed	Feb 1, 2008	Apr 1, 2009	Alzheimer's Disease
NCT00566501	Phase 3	Completed	Dec 14, 2007	Apr 1, 2010	Alzheimer's Disease
NCT01023867	Pre-clinical	Completed	Mar 1, 2007	Jun 1, 2010	Alzheimer's Disease
NCT00381381	Approved	Completed	May 31, 2006	Dec 31, 2008	Alzheimer's Disease
NCT00220896	Approved	Completed	Jan 1, 2006	Mar 1, 2009	Cognitively Normal Elderly Individuals

Other Products from Eisai

MecobalaminApproved

MonteplaseApproved

E2020 + PlaceboApproved

Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved

DonepezilApproved